Free LLS Education Program: Keys to Accurate Lymphoma Diagnoses
The latest telephone/web education program from the Leukemia & Lymphoma Society is on an especially interesting and valuable topic: keys to an accurate diagnosis in non-Hodgkin's lymphoma.
Date: December 12, 2014
Time: 12:00 noon Eastern / 9:00 AM Pacific
Speaker: Dr. Stephen Schuster MD
Dr. Schuster is the Director of the Lymphoma Program and Lymphoma Translational Research, and Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma at the Abramson Cancer Center, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA. Read more about Dr. Schuster at Penn Medicine.
Dr. Schuster's published research includes, but is not limited to, work in the following subtypes:
- Double-hit lymphoma
- Cutaneous T-cell lymphoma
- Follicular lymphoma
- DLBCL
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Multiple myeloma
- Therapeutic lymphoma vaccines
- Marginal zone lymphoma
- MALT lymphoma
- Stem cell transplants
- Extremely rare lymphomas, such as primary cardiac lymphoma and primary lymphomas of the cervix and uterus
T-cell prolymphocytic lymphoma
Participation requires registration but is, as always, free. Those who take part in this education program will learn important information about:
- Why an accurate diagnosis is so important in lymphoma
- How one's diagnosis dictates treatment options
- Emerging therapies for NHLs
- Tests used by pathologists to make an accurate lymphoma diagnosis
And much, much more. You can register by phone by calling 866-992-9950 ext. 303 or click on this link to register online.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
